Cytokeratin 16/CK16/KRT16
Use
Cytokeratin 16 (KRT16) is expressed in several types of epithelial tissues. Studies have shown upregulated KRT16 during wound healing, in neoplasms, and in hyperproliferative disorders such as benign keratinocyte hyperplasia, psoriasis, and chronic contact dermatitis.
Special Instructions
Not provided.
Limitations
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract. Specimens must be fixed in 10% NBF or B plus. All other fixatives will be rejected.
Methodology
Immunoassay (IHC)
Biomarkers
KRT16
Protein
Result Turnaround Time
2 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (Fresh)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Fixative should be at a 20:1 fixative to tissue ratio, 10% neutral buffered formalin (NBF) for 6-72 hours (48-72 hours PREFERRED)
Storage Instructions
15°C to 25°C
Causes for Rejection
Specimens must be fixed in 10% NBF or B plus. All other fixatives will be rejected.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | ≤ 72 Hours |